The sarcoglycan complex in striated and vascular smooth muscle

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 67, Issue , 2002, Pages 389-397

  Wheeler, M T ^a   Allikian, M J ^a   Heydemann, A ^a   McNally, E M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; SARCOGLYCAN; DYSTROPHIN GLYCOPROTEIN COMPLEX; GLYCOPROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CARDIOMYOPATHY; CELL DEGENERATION; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; DISEASE ASSOCIATION; HEART FAILURE; MOUSE; MUSCLE ATROPHY; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; VASCULAR SMOOTH MUSCLE; VASOSPASM; ARTICLE; CORONARY ARTERY SPASM; GENETIC DISORDER; HUMAN; MECHANOTRANSDUCTION; MOLECULAR DYNAMICS; MUSCULAR DYSTROPHY; SMOOTH MUSCLE; STRIATED MUSCLE;

ANIMALIA;

EID: 0038463507     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2002.67.389     Document Type: Conference Paper

References (81)

1. Adams M.E., Mueller H.A., and Froehner S.C. 2001. In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization ofnNOS and aquaporin-4. J. Cell Biol. 155: 113.
2. Aguilar-Bryan L., Nichols C.G., Wechsler S.W., Clement J.P., IV, Boyd A.E., III, Gonzalez G., Herrera-Sosa H., Nguy K., Bryan J., and Nelson D.A. 1995. Cloning of the beta cell high-affinity sulfonylurea receptor: A regulator of insulin secretion. Science 268: 423.
3. Allamand V. and Campbell K.P. 2000. Animal models for muscular dystrophy: Valuable tools for the development of therapies. Hum. Mol. Genet. 9: 2459.
4. Ashcroft F.M. and Gribble F.M. 1998. Correlating structure and function in ATP-sensitive K+ channels. Trends Neurosci. 21: 288.
5. Babenko A.P., Aguilar-Bryan L., and Bryan J. 1998. A view of sur/KIR6.X, KATP channels. Annu. Rev. Physiol. 60: 667.
6. Barresi R., Moore S.A., Stolle C.A., Mendell J.R., and Campbell K.P. 2000. Expression of gamma-sarcoglycan in smooth muscle and its interaction with the smooth muscle sarcoglycansarcospan complex. J. Biol. Chem. 275: 38554.
7. Ben Hamida M., Ben Hamida C., Zouari M., Belal S., and Hentati F. 1996. Limb-girdle muscular dystrophy 2C: Clinical aspects. Neuromuscul. Disord. 6: 493.
8. Bonnemann C.G., McNally E.M., and Kunkel L.M. 1996. Beyond dystrophin: Current progress in the muscular dystrophies. Curr. Opin. Pediatr. 8: 569.
9. Bonnemann C.G., Modi R., Noguchi S., Mizuno Y., Yoshida M., Gussoni E., McNally E.M., Duggan D.J., Angelini C., and Hoffman E.P. 1995. Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat. Genet. 11: 266.
10. Calvo F., Teijeira S., Fernandez J.M., Teijeiro A., Fernandez Hojas R., Fernandez-Lopez X.A., Martin E., and Navarro C. 2000. Evaluation of heart involvement in gamma-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromuscul. Disord. 10: 560.
11. Chamberlain J.S., Corrado K., Rafael J.A., Cox G.A., Hauser M., and Lumeng C. 1997. Interactions between dystrophin and the sarcolemma membrane. Soc. Gen. Physiol. Ser. 52: 19.
12. Chutkow W.A., Simon M.C., Le Beau M.M., and Burant C.F. 1996. Cloning, tissue expression, and chromosomal localization of SUR2, the putative drug-binding subunit of cardiac, skeletal muscle, and vascular KATP channels. Diabetes 45: 1439.
13. Chutkow W.A., Pu J., Wheeler M.T., Wada T., Makielski J., Burant C.F., and McNally E.M. 2002. Hypertension and episodic coronary artery vasospasm in mice deficient for SUR2 KATP channels. J. Clin. Invest. 110: 203.
14. Chutkow W.A., Samuel V., Hansen P.A., Pu J., Valdivia C.R., Makielski J.C., and Burant C.F. 2001. Disruption of Sur2-containing K(ATP) channels enhances insulin-stimulated glucose uptake in skeletal muscle. Proc. Natl. Acad. Sci. 98: 11760.
15. Codd M.B., Sugrue D.D., Gersh B.J., and Melton L.J., III. 1989. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 80: 564.
16. Cohn R.D. and Campbell K.P. 2000. Molecular basis of muscular dystrophies. Muscle Nerve 23: 1456.
17. Cohn R.D., Durbeej M., Moore S.A., Coral-Vazquez R., Prouty S., and Campbell K.P. 2001. Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex. J. Clin. Invest. 107: R1.
18. Coral-Vazquez R., Cohn R.D., Moore S.A., Hill J.A., Weiss R.M., Davisson R.L., Straub V., Barresi R., Bansal D., Hrstka R.F., Williamson R., and Campbell K.P. 1999. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: A novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98: 465.
19. Cordier L., Gao G.P., Hack A.A., McNally E.M., Wilson J.M., Chirmule N., and Sweeney H.L. 2001. Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther. 12: 205.
20. Cordier L., Hack A.A., Scott M.O., Barton-Davis E.R., Gao G., Wilson J.M., McNally E.M., and Sweeney H.L. 2000. Rescue of skeletal muscles of gamma-sarcoglycan-deficient mice with adeno-associated virus-mediated gene transfer. Mol. Ther. 1: 119.
21. Coulton G.R., Morgan J.E., Partridge T.A., and Sloper J.C. 1988. The mdx mouse skeletal muscle myopathy. I. A histological, morphometric and biochemical investigation. Neuropathol. Appl. Neurobiol. 14: 53.
22. Cox G.A., Phelps S.F., Chapman V.M., and Chamberlain J.S. 1993. New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. Nat. Genet. 4: 87.
23. Crosbie R.H., Straub V., Yun H.Y., Lee J.C., Rafael J.A., Chamberlain J.S., Dawson V.L., Dawson T.M., and Campbell K.P. 1998. mdx muscle pathology is independent of nNOS perturbation. Hum. Mol. Genet. 7: 823.
24. Danialou G., Comtois A.S., Dudley R., Karpati G., Vincent G., Des Rosiers C., and Petrof B.J. 2001. Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. FASEB J. 15: 1655.
25. Deconinck A.E., Rafael J.A., Skinner J.A., Brown S.C., Potter A.C., Metzinger L., Watt D.J., Dickson J.G., Tinsley J.M., and Davies K.E. 1997. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717.
26. Donoghue M., Ernst H., Wentworth B., Nadal-Ginard B., and Rosenthal N. 1988. A muscle-specific enhancer is located at the 3′ end of the myosin light-chain 1/3 gene locus. Genes Dev. 2: 1779.
27. Emery A.E. 2002. The muscular dystrophies. Lancet 359: 687.
28. Ervasti J.M. and Campbell K.P. 1991. Membrane organization of the dystrophin-glycoprotein complex. Cell 66: 1121.
29. Ervasti J.M., Ohlendieck K., Kahl S.D., Gaver M.G., and Campbell K.P. 1990. Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315.
30. Ettinger A.J., Feng G., and Sanes J.R. 1997. Epsilon-sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D. J. Biol. Chem. 272: 32534.
31. Factor S.M., Minase T., Cho S., Dominitz R., and Sonnenblick E.H. 1982. Microvascular spasm in the cardiomyopathic Syrian hamster: A preventable cause of focal myocardial necrosis. Circulation 66: 342.
32. Ganz P., Weidinger F.F., Yeung A.C., Vekshtein V.I., Vita J.A., Ryan T.J., Jr., McLenachan J.M., and Selwyn A.P. 1991. Coronary vasospasm in humans: The role of atherosclerosis and of impaired endothelial vasodilator function. Basic Res. Cardiol. 86: 215.
33. Gossett L.A., Kelvin D.J., Sternberg E.A., and Olson E.N. 1989. A new myocyte-specific enhancer-binding factor that recognizes a conserved element associated with multiple musclespecific genes. Mol. Cell. Biol. 9: 5022.
34. Grady R.M., Teng H., Nichol M.C., Cunningham J.C., Wilkinson R.S., and Sanes J.R. 1997. Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: A model for Duchenne muscular dystrophy. Cell 90: 729.
35. Grady R.M., Grange R.W., Lau K.S., Maimone M.M., Nichol M.C., Stull J.T., and Sanes, J.R. 1999. Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat. Cell Biol. 1: 215.
36. Hack A.A., Groh M.E., and McNally E.M. 2000a. Sarcoglycans in muscular dystrophy. Microsc. Res. Tech. 48: 167.
37. Hack A.A., Cordier L., Shoturma D.I., Lam M.Y., Sweeney H.L., and McNally E.M. 1999. Muscle degeneration without mechanical injury in sarcoglycan deficiency. Proc. Natl. Acad. Sci. 96: 10723.
38. Hack A.A., Ly C.T., Jiang F., Clendenin C.J., Sigrist K.S., Wollmann R.L., and McNally E.M. 1998. Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J. Cell Biol. 142: 1279.
39. Hack A.A., Lam M.Y., Cordier L., Shoturma D.I., Ly C.T., Hadhazy M.A., Hadhazy M.R., Sweeney H.L., and McNally E.M. 2000b. Differential requirement for individual sarcoglycans and dystrophin in the assembly and function of the dystrophin-glycoprotein complex. J. Cell Sci. 113: 2535.
40. Henry M.D. and Campbell K.P. 1998. A role for dystroglycan in basement membrane assembly. Cell 95: 859.
41. Heydemann A., Wheeler M.T., and McNally E.M. 2001. Cardiomyopathy in animal models of muscular dystrophy. Curr. Opin. Cardiol. 16: 211.
42. Johnson J.E., Wold B.J., and Hauschka S.D. 1989. Muscle creatine kinase sequence elements regulating skeletal and cardiac muscle expression in transgenic mice. Mol. Cell. Biol. 9: 3393.
43. Lim L.E., Duclos F., Broux O., Bourg N., Sunada Y., Allamand V., Meyer J., Richard I., Moomaw C., Slaughter C., et al. 1995. Beta-sarcoglycan: Characterization and role in limbgirdle muscular dystrophy linked to 4q12. Nat. Genet. 11: 257.
44. Matsuda R., Nishikawa A., and Tanaka H. 1995. Visualization of dystrophic muscle fibers in mdx mouse by vital staining with Evans blue: Evidence of apoptosis in dystrophin-deficient muscle. J. Biochem. 118: 959.
45. McNally E.M., Ly C.T., and Kunkel L.M. 1998. Human epsilon-sarcoglycan is highly related to alpha-sarcoglycan (adhalin), the limb girdle muscular dystrophy 2D gene. FEBS Lett. 422: 27.
46. McNally E.M., Passos-Bueno M.R., Bonnemann C.G., Vainzof M., de Sa Moreira E., Lidov H.G., Othmane K.B., Denton P.H., Vance J.M., Zatz M., and Kunkel L.M. 1996a. Mild and severe muscular dystrophy caused by a single gamma-sarcoglycan mutation. Am. J. Hum. Genet. 59: 1040.
47. McNally E.M., Duggan D., Gorospe J.R., Bonnemann C.G., Fanin M., Pegoraro E., Lidov H.G., Noguchi S., Ozawa E., Finkel R.S., Cruse R.P., Angelini C., Kunkel L.M., and Hoffman E.P. 1996b. Mutations that disrupt the carboxyl-terminus of gamma-sarcoglycan cause muscular dystrophy. Hum. Mol. Genet. 5: 1841.
48. Megeney L.A., Kablar B., Perry R.L., Ying C., May L., and Rudnicki M.A. 1999. Severe cardiomyopathy in mice lacking dystrophin and MyoD. Proc. Natl. Acad. Sci. 96: 220.
49. Melacini P., Vianello A., Villanova C., Fanin M., Miorin M., Angelini C., and Dalla Volta S. 1996. Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy. Neuromuscul. Disord. 6: 367.
50. Melacini P., Fanin M., Duggan D.J., Freda M.P., Berardinelli A., Danieli GA., Barchitta A., Hoffman E.P., Dalla Volta S., and Angelini C. 1999. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 22: 473.
51. Miki T., Suzuki M., Shibasaki T., Uemura H., Sato T., Yamaguchi K., Koseki H., lwanaga T., Nakaya H., and Seino S. 2002. Mouse model of Prinzmetal angina by disruption of the inward rectifier Kir6.1. Nat. Med. 8: 466.
52. Nigro V., de Sa Moreira E., Piluso G., Vainzof M., Belsito A., Politano L., Puca A.A., Passos-Bueno M.R., and Zatz M. 1996a. Autosomal recessive limb-girdle muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. Nat. Genet. 14: 195.
53. Nigro V., Okazaki Y., Belsito A., Piluso G., Matsuda Y., Politano L., Nigro G., Ventura C., Abbondanza C., Molinari A.M., Acampora D., Nishimura M., Hayashizaki Y., and Puca G.A. 1997. Identification of the Syrian hamster cardiomyopathy gene. Hum. Mol. Genet. 6: 601.
54. Nigro V., Piluso G., Belsito A., Politano L., Puca A.A., Papparella S., Rossi E., Viglietto G., Esposito M.G., Abbondanza C., Medici N., Molinari A.M., Nigro G., and Puca G.A. 1996b. Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. Hum. Mol. Genet. 5: 1179.
55. Noguchi S., McNally E.M., Ben Othmane K., Hagiwara Y., Mizuno Y., Yoshida M., Yamamoto H., Bonnemann C.G., Gussoni E., Denton P.H., et al. 1995. Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 270: 819.
56. Perloff J.K., de Leon A.C., Jr., and O'Doherty D. 1966. The cardiomyopathy of progressive muscular dystrophy. Circulation 33: 625.
57. Petrof B.J., Shrager J.B., Stedman H.H., Kelly A.M., and Sweeney H.L. 1993. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. 90: 3710.
58. Piccolo F., Jeanpierre M., Leturcq F., Dode C., Azibi K., Toutain A., Merlini L., Jarre L., Navarro C., Krishnamoorthy R., Tome F.M., Urtizberea J.A., Beckmann J.S., Campbell K.P., and Kaplan J.C. 1996. A founder mutation in the gammasarcoglycan gene of gypsies possibly predating their migration out of India. Hum. Mol. Genet. 5: 2019.
59. Piras G., El Kharroubi A., Kozlov S., Escalante-Alcalde D., Hernandez L., Copeland N.G., Gilbert D.J., Jenkins N.A., and Stewart C.L. 2000. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: Identification by a subtractive screen of novel uniparental fibroblast lines. Mol. Cell. Biol. 20: 3308.
60. Quayle J.M., Nelson M.T., and Standen N.B. 1997. ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 77: 1165.
61. Rafael J.A. and Brown S.C. 2000. Dystrophin and utrophin: Genetic analyses of their role in skeletal muscle. Microsc. Res. Tech. 48: 155.
62. Sakamoto A., Ono K., Abe M., Jasmin G., Eki T., Murakami Y., Masaki T., Toyo-oka T., and Hanaoka F. 1997. Both hypertrophic and dilated cardiomyopathies are caused by mutation of the same gene, delta-sarcoglycan, in hamster: An animal model of disrupted dystrophin-associated glycoprotein complex. Proc. Natl. Acad. Sci. 94: 13873.
63. Sander M., Chavoshan B., Harris S.A., lannaccone S.T., Stull J.T., Thomas G.D., and Victor R.G. 2000. Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. 97: 13818.
64. Seidman J.G. and Seidman C. 2001. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. Cell 104: 557.
65. Seino S. 1999. ATP-sensitive potassium channels: A model of heteromultimeric potassium channel/receptor assemblies. Annu. Rev. Physiol. 61: 337.
66. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., and Barnard P.J. 1989. The molecular basis of muscular dystrophy in the mdx mouse: A point mutation. Science 244: 1578.
67. Sonnenblick E.H., Fein F., Capasso J.M., and Factor S.M. 1985. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. Am. J. Cardiol. 55: 179B.
68. Straub V., Rafael J.A., Chamberlain J.S., and Campbell K.P. 1997. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J. Cell Biol. 139: 375.
69. Straub V., Ettinger A.J., Durbeej M., Venzke D.P., Cutshall S., Sanes J.R., and Campbell K.P. 1999. epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. J. Biol. Chem. 274: 27989.
70. Sueda S., Ochi N., Kawada H., Matsuda S., Hayashi Y., Tsuruoka T., and Uraoka T. 1999. Frequency of provoked coronary vasospasm in patients undergoing coronary arteriography with spasm provocation test of acetylcholine. Am. J. Cardiol. 83: 1186.
71. Thomas G.D., Sander M., Lau K.S., Huang P.L., Stull J.T., and Victor R.G. 1998. Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. 95: 15090.
72. Tinsley J.M., Potter A.C., Phelps S.R., Fisher R., Trickett J.I., and Davies K.E. 1996. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384: 349.
73. Towbin J.A. and Bowles N.E. 2001. Molecular genetics of left ventricular dysfunction. Curr. Mol. Med. 1: 81.
74. Wheeler M.T., Zarnegar S., and McNally E.M. 2002. ζ-sarcoglycan is a novel component of the dystrophin-glycoprotein complex. Hum. Mol. Gen. 11: 2147.
75. Yokoshiki H., Sunagawa M., Seki T., and Sperelakis N. 1998. ATP-sensitive K+ channels in pancreatic, cardiac, and vascular smooth muscle cells. Am. J. Physiol. 274: C25.
76. Yoshida M. and Ozawa E. 1990. Glycoprotein complex anchoring dystrophin to sarcolemma. J. Biochem. 108: 748.
77. Yoshida M., Hama H., Ishikawa-Sakurai M., Imamura M., Mizuno Y., Araishi K., Wakabayashi-Takai E., Noguchi S., Sasaoka T., and Ozawa E. 2000. Biochemical evidence for association of dystrobrevin with the sarcoglycan-sarcospan complex as a basis for understanding sarcoglycanopathy. Hum. Mol. Genet. 9: 1033.
78. Yoshida T., Pan Y., Hanada H., Iwata Y., and Shigekawa M. 1998. Bidirectional signaling between sarcoglycans and the integrin adhesion system in cultured L6 myocytes. J. Biol. Chem. 273: 1583.
79. Zhu X., Wheeler M.T., Hadhazy M., Lam M.Y., and McNally E.M. 2002. Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB J. 8: 8.
80. Zhu X., Hadhazy M., Groh M.E., Wheeler M.T., Wollmann R., and McNally E.M. 2001. Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of sarcoglycan assembly. J. Biol. Chem. 276: 21785.
81. Zimprich A., Grabowski M., Asmus F., Naumann M., Berg D., Bertram M., Scheidtmann K., Kern P., Winkelmann J., Muller-Myhsok B., Riedel L., Bauer M., Muller T., Castro M., Meitinger T., Strom T.M., and Gasser T. 2001. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonusdystonia syndrome. Nat. Genet. 29: 66.